Arrhythmias & electrophysiology
Very High-Power Short-Duration, Temperature-Controlled Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: The Prospective Multicenter Q-FFICIENCY Trial
Authors' conclusion
Temperature-controlled paroxysmal AF ablation with the novel QDM catheter in vHPSD mode (90 W, ≤4 seconds), alone or with CPTC mode (25 to 50 W), is highly efficient and effective without compromising safety.
Study context
- Population
- Patients with drug-refractory, symptomatic paroxysmal atrial fibrillation (AF)166 met eligibility, ablated
- Participants
- 191 patients
- Outcome
- Safety: primary adverse events within ≤7 days of ablation; effectiveness: freedom from documented atrial tachyarrhythmia recurrence and acute procedural, repeat ablation and antiarrhythmic drug failure
- Follow-up
- 12 months (effectiveness)
Methodological detailsmulticentre, single-group
- Multicentre
- Single-group
Main finding
As reported in the abstract
Kaplan-Meier estimated 12-month primary effectiveness success rate
76.7%
Observational data: associations, not effects.
Further findings
Freedom from atrial tachyarrhythmia recurrence, clinical success (freedom from symptomatic recurrence), freedom from repeat ablation (Kaplan-Meier estimates) · 12 months
- Freedom from atrial tachyarrhythmia recurrence
- 82.1%
- Clinical success (freedom from symptomatic recurrence)
- 86.0%
- Freedom from repeat ablation
- 92.1%
Procedural metrics (median times)
- Median procedural time (minutes)
- 132.0
- Median radiofrequency (RF) application time for ablating pulmonary vein (PVs) (minutes)
- 8.0
- Median fluoroscopy time (minutes)
- 9.1
Safety
Primary adverse events (primary safety endpoint) · ≤7 days of ablation
- Primary adverse event rate
- 3.6%
Moderate or severe PV stenosis on imaging (subset, n = 40) · 3 months
- Imaging did not show moderate or severe PV stenosis
- Subset of participants (n = 40)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →